Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Net Income (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Net Income for 16 consecutive years, with $40000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 92.93% to $40000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $10.1 million, a 618.29% increase, with the full-year FY2024 number at -$124000.0, up 96.82% from a year prior.
  • Net Income was $40000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $42000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $11.0 million in Q1 2025 to a low of -$2.8 million in Q4 2023.
  • A 5-year average of $65000.0 and a median of -$289000.0 in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 254.95% in 2023, then skyrocketed 3906.23% in 2025.
  • NovaBay Pharmaceuticals' Net Income stood at -$158000.0 in 2021, then surged by 1620.25% to $2.4 million in 2022, then tumbled by 216.28% to -$2.8 million in 2023, then soared by 65.45% to -$965000.0 in 2024, then soared by 104.15% to $40000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Net Income are $40000.0 (Q3 2025), $42000.0 (Q2 2025), and $11.0 million (Q1 2025).